TD Cowen Initiates Coverage on Repligen (NASDAQ:RGEN)

TD Cowen assumed coverage on shares of Repligen (NASDAQ:RGEN) in a research report sent to investors on Monday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $200.00 price target on the biotechnology company’s stock.

A number of other research analysts also recently weighed in on RGEN. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. Wolfe Research began coverage on Repligen in a report on Thursday, November 14th. They set a “peer perform” rating on the stock. Canaccord Genuity Group began coverage on Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. Canaccord Genuity Group began coverage on Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. Finally, HC Wainwright lowered their price target on Repligen from $240.00 to $180.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. Six investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $186.00.

Repligen Stock Down 2.5 %

Shares of Repligen stock opened at $145.72 on Monday. The stock’s fifty day moving average is $155.45 and its 200-day moving average is $149.14. The firm has a market capitalization of $8.16 billion, a PE ratio of -393.83, a price-to-earnings-growth ratio of 4.54 and a beta of 0.99. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen has a 12-month low of $113.50 and a 12-month high of $211.13.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. The company had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. Repligen’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.23 earnings per share. Equities analysts anticipate that Repligen will post 1.54 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Signaturefd LLC boosted its stake in shares of Repligen by 172.2% during the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 124 shares in the last quarter. Sava Infond d.o.o. bought a new stake in shares of Repligen during the 4th quarter worth about $29,000. UMB Bank n.a. boosted its stake in shares of Repligen by 138.3% during the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 130 shares in the last quarter. Blue Trust Inc. boosted its stake in shares of Repligen by 113.4% during the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 127 shares in the last quarter. Finally, Resources Management Corp CT ADV bought a new stake in shares of Repligen during the 3rd quarter worth about $37,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.